<DOC>
	<DOCNO>NCT01162395</DOCNO>
	<brief_summary>The main purpose study investigate safety tolerability AZD3514 give orally patient castration-resistant prostate cancer ( CRPC )</brief_summary>
	<brief_title>Open Label Prostate Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males age 20 year old . Histologically Cytologically proven diagnosis prostate cancer standard therapy currently consider appropriate . Documented evidence metastatic prostate cancer Presence progressive disease define one : Biochemical progression prostate cancer Progression define Response Evaluation Criteria Solid Tumours ( RECIST ) 1.1 guideline Two new metastatic bone lesion bone scan previous assessment Serum testosterone concentration less equal 50 ng/dL World Health Organization ( WHO ) performance status 0 1 deterioration previous 2 week minimum life expectancy 12 week . Sexually active male willing use condom For inclusion AZD3514 administer combination abiraterone acetate cohort ( ) , patient must : Have receive prior chemotherapy contain base docetaxel Not receive prior treatment abiraterone acetate , MDV3100 , TAK700 , TOK001 similar therapy target AR axis selective AR downregulatorlike property For inclusion AZD3514 administer combination abiraterone acetate patient currently receive abiraterone acetate cohort ( ) , patient must : 1 . Have stable abiraterone acetate abiraterone acetate ≥ 4 month ( i.e . stable PSA value ) achieve ≥ 50 % reduction PSA treat abiraterone acetate 2 . Have evidence biochemical progression ( PSA ) prostate cancer , define inclusion number 5 ( except withdrawal abiraterone acetate antiandrogen therapy ) For inclusion pair ( lesion ) tumour biopsy research , patient must : 1 . Provide informed consent pair tumour biopsy sample 2 . Have bone soft tissue lesion suitable paired biopsy sample Any unresolved toxicity prior therapy great Common Terminology Criteria Adverse Events ( CTCAEv4 ) grade 1 except alopecia toxicity relate use gonadotropinreleasing hormone agonist Medically important spinal cord compression brain metastasis Medically important evidence severe uncontrolled systemic disease History hypersensitivity active inactive excipients AZD3514 drug similar chemical structure class AZD3514 Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate product previous significant bowel resection would preclude adequate absorption AZD3514 Inadequate bone marrow reserve organ function Any medically important factor identify electrocardiogram ( ECG ) measurement Concurrent recent treatment certain medication medical procedure The follow criterion exclude patient enter AZD3514 administer combination abiraterone acetate cohort ( ) : As judged investigator , evidence severe uncontrolled systemic disease condition , include adrenocortical insufficiency history cardiovascular disease include heart failure ( currently randomize data use abiraterone acetate patient LVEF &lt; 50 % NYHA Class III IV heart failure ) , would make undesirable patient participate trial . See full local prescribe information abiraterone acetate detail ChildPugh class B C hepatic impairment If unable fast ≥ 2 hour prior take dose ≥ 1 hour post dose Received abiraterone acetate treatment previously Known hypersensitivity component prednisone prednisolone Any systemic fungal infection</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Castration Resistant</keyword>
	<keyword>Prostate Androgen Receptor Down Regulator</keyword>
	<keyword>Metastatic</keyword>
</DOC>